Search

Displaying results 3151 - 3160 of 4539 in total
  1. Drug

    RLYB212

    go.drugbank.com/drugs/DB17727
    Investigational

    It is currently being developed by Rallybio for the prevention of fetal and neonatal alloimmune thrombocytopenia.

  2. Drug

    SAR-439459

    go.drugbank.com/drugs/DB17864
    Investigational

    [A259862] Developed by Sanofi, it is being investigated for the treatment of cancers and Osteogenesis Imperfecta.

  3. Drug

    Butyrylthiocholine

    go.drugbank.com/drugs/DB04250
    Experimental

    A sulfur-containing analog of butyrylcholine which is hydrolyzed by butyrylcholinesterase to butyrate and thiocholine. It is used as a reagent in the determination of butyrylcholinesterase activity.

  4. Drug

    Toripalimab

    go.drugbank.com/drugs/DB15043
    ApprovedInvestigational

    One mechanism by which this occurs is through the overexpression of programmed cell death ligand (PD-L1)[A261506] - the binding of PD-L1 (and PD-L2) to its target receptor (PD-1) results in the inhibition

  5. Drug

    Manganese cation

    go.drugbank.com/drugs/DB06757
    ApprovedInvestigationalNutraceutical

    [A263687, A263662] In humans, manganese regulates several physiological processes by acting as a cofactor for proteins [A263657, A263662, A263667] making it an essential metal for normal development and

    Mixtures: Pnv-VP-U
  6. Drug

    Inositol nicotinate

    go.drugbank.com/drugs/DB08949
    ApprovedWithdrawn

    It is associated with reduced flushing compared to other vasodilators by being broken down into the metabolites and inositol at a slower rate.

  7. Drug

    MaxAdFVIII

    go.drugbank.com/drugs/DB17713
    Experimental

    First developed by GenStar, it is being investigated for the treatment of hemophilia.

  8. Drug

    ATL1102

    go.drugbank.com/drugs/DB04997
    Investigational

    It works by entering cells and targeting genes.

  9. Drug

    SB-249553

    go.drugbank.com/drugs/DB05285
    Experimental

    It is also under by GlaxoSmithKline to treat melanoma and lung cancer.

  10. Drug

    Befunolol

    go.drugbank.com/drugs/DB09013
    Experimental

    Befunolol is a beta blocker introduced in 1983 by Kakenyaku Kakko. It is currently in experimental status, and is being tested for the management of open angle glaucoma.